Scott A. Clarke
Architects in Eugene, OR
License number
Oregon 5035
Issued Date
Oct 7, 2005
Expiration Date
Dec 31, 2017
Category
Architecture
Address
Address
Eugene, OR 97401
Professional information
Associate At Pivot Architecture
Position:
Associate at PIVOT Architecture
Location:
Eugene, Oregon Area
Industry:
Architecture & Planning
Work:
PIVOT Architecture
since Jun 2000
-
Associate
Education:
University of Oregon 1997 - 2000
M.Arch, Architecture University of Oregon 1997 - 2000
University of Nevada, Reno 1982 - 1985
BA, Art
M.Arch, Architecture University of Oregon 1997 - 2000
University of Nevada, Reno 1982 - 1985
BA, Art
Scientist At Molecular Probes
Position:
Scientist at Molecular Probes, Senior Scientist at Invitrogen, scientist at Invitrogen/ Life Technologies
Location:
Eugene, Oregon Area
Industry:
Biotechnology
Work:
Molecular Probes
-
Scientist
Invitrogen
since 2002
-
Senior Scientist
Invitrogen/ Life Technologies
since 2001
-
scientist
motorola
1998 - 2002
-
biologist
Dual Labeling Methods For Measuring Cellular Proliferation
US Patent:
2011011, May 19, 2011
Filed:
May 14, 2009
Appl. No.:
12/993079
Inventors:
Scott Clarke - Eugene OR, US
Jolene Bradford - Eugene OR, US
Jolene Bradford - Eugene OR, US
Assignee:
LIFE TECHNOLOGIES CORPORATION - Carlsbad CA
International Classification:
C40B 30/06, C12Q 1/68
US Classification:
506 10, 435 6
Abstract:
The present invention provides a method for measuring cellular nascent nucleic acid synthesis by dual pulse labeling of nucleic acid. The first pulse labeling of nucleic acid with a nucleoside analog allows establishment of a baseline nucleic acid synthesis rate. Pulse labeling of the nucleic acid with a second nucleoside analog then allows measurement of any changes to nucleic acid synthesis. The nucleic acid synthesis can be measured as cell proliferation, DNA, or gene expression, RNA. This method does not require a potentially artifact-inducing intermediary wash step between pulse labels. Additionally, this method may be used to screen compounds for their affect on cellular proliferation by treating cells or an organism with the test compound simultaneous to or before treatment with a competitive nucleoside analog.